Craig Menear will succeed Frank Blake as Home Depot's new CEO, reports "Squawk Box's" Becky Quick.» Read More
I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon story.
The Democratic-controlled Congress Thursday approved budget blueprints embracing President Barack Obama's agenda but leaving many hard choices until later and a government deeply in the red.
Leaders from around the globe made headway Thursday on tackling the world's worst financial crisis since the 1930s, with signs of agreements to give more money to the International Monetary Fund, clamp down on tax havens and tighten regulation over freewheeling hedge funds.
"If there is a secret to Dimon’s success, it may simply be this: unlike many Wall Street executives he has a capacity for continual, critical self-examination, both of himself and the organization he runs," writes author Patricia Crisafulli.
It was a mistake to take so much TARP money from the government and, unfortunately, it will take a while to pay back Ken Lewis, the chief executive of Bank of America, told CNBC Thursday.
Individual performance doesn't seem to matter when it comes to manager salaries. It's all about what the next guy makes.
March sales fell sharply for General Motors, Ford Motor and Chrysler, but not as much as industry analysts had feared for any of the companies. Sales of Japanese automobiles also fell, though less steeply than they did for U.S. automakers.
Auto industry legends weigh in on President Obama’s push for the right solution.
Automakers were set to release their March U.S. vehicles sales on Tuesday amid continued uncertainty about the future of U.S.-based car makers.
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
U.S. President Barack Obama said on Wednesday there was "enormous consensus" between the world's largest developed and emerging economies on plans to haul the world out of the deepest downturn since the 1930s.
The president's position on GM has not changed since Monday, a senior administration official said when asked to comment on a Bloomberg report which said Obama had determined a prepackaged bankruptcy was the best way for GM to restructure.
A prestigious peer-reviewed journal is proposing taking a hardline stance on what it calls the "pervasive" funding relationship between drug and medical device companies and professional medical associations.
Even the business world's worst executives are making big money. So much for performance-based compensation.
Warren Buffett's official biographer calls Byron Trott a "perfect candidate" to eventually take over at Berkshire Hathaway, now that Buffett's favorite investment banker has left Goldman Sachs. But another prominent Buffett watcher says there's "no chance."
Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.
President Barack Obama ordered General Motors and Chrysler to accelerate their survival efforts and brace for possible bankruptcy, saying neither company had done enough to justify the taxpayer money they were seeking.
With members of President Obama's Auto Task Force hitting the ground in Detroit, the re-structuring of General Motors kicks into gear. Monday in Washington may have been all about justifying and selling the government calling the shots at GM, but Tuesday in Detroit is when the president's people get to work. No wonder critics are now saying GM now stands for Government Motors, not General Motors. So what happens next?
That’s a tough question in this market. So Cramer interviewed the CEO to find out.
There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.